Anna Nappi, Guglielmo Nasti, Carmela Romano, Massimiliano Berretta and Alessandro Ottaiano* Pages 2779 - 2791 ( 13 )
<p>Colorectal cancer represents the third most frequently occurring cancer worldwide. In the last decade, the survival of patients affected by metastatic colorectal cancer (mCRC) has improved through the introduction of biological drugs. However, in this new and dynamic therapeutic context, research about prognostic and predictive factors is important to guide the oncologists to effective therapies as well as to improve the understanding of colorectal cancer biology. Their identification is an intensive area of research and our future goal will be to depict tumour-specific "molecular signatures" in order to predict the clinical course of the disease and the best treatments. <p> In this report, we describe clinical, pathological and molecular biomarkers that can play a role as prognostic or predictive factors in mCRC.</p>
Colorectal cancer, metastases, prognostic factors, predictive factors, biologic therapy, chemotherapy.
Abdominal medical oncology, National Cancer Institute, Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”, Naples, SSD-Innovative Therapies for Abdominal Metastases, Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”, Naples, Abdominal medical oncology, National Cancer Institute, Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”, Naples, Department of Medical Oncology, National Cancer Institute (CRO), Aviano (PN), SSD-Innovative Therapies for Abdominal Metastases, Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”, Naples